Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway

Free Radical Biology and Medicine

Volumn 89, Issue , 2015, Pages 287-299

  Leone, Alessandra ^a   Roca, Maria Serena ^a   Ciardiello, Chiara ^a   Terranova Barberio, Manuela ^a   Vitagliano, Carlo ^a   Ciliberto, Gennaro ^a   Mancini, Rita ^b   Di Gennaro, Elena ^a   Bruzzese, Francesca ^a   Budillon, Alfredo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

EGFR tyrosine kinase inhibitors; HDACi; KEAP1; NRF2; NSCLC cancer; Oxidative stress; ROS; VDAC1

Indexed keywords

ERLOTINIB; GEFITINIB; KELCH LIKE ECH ASSOCIATED PROTEIN 1; PORIN; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; VOLTAGE DEPENDENT ANION CHANNEL; VOLTAGE DEPENDENT ANION CHANNEL 1; VORINOSTAT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; HYDROXAMIC ACID; KEAP1 PROTEIN, HUMAN; MESSENGER RNA; MYC PROTEIN; MYC PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SIGNAL PEPTIDE; VDAC1 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DRUG DOSE REDUCTION; DRUG POTENTIATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; NON SMALL CELL LUNG CANCER; ONCOGENE C MYC; OXIDATIVE STRESS; PRIORITY JOURNAL; UPREGULATION; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOVEMENT; CELL PROLIFERATION; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; NF-E2-RELATED FACTOR 2; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MYC; QUINAZOLINES; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; VOLTAGE-DEPENDENT ANION CHANNEL 1;

EID: 84943183403     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2015.07.155     Document Type: Article

References (66)

1. M. Jakopovic, A. Thomas, S. Balasubramaniam, D. Schrump, G. Giaccone, and S.E. Bates Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy Front Oncol 3 2013 261
2. F. Janku, D.J. Stewart, and R. Kurzrock Targeted therapy in non-small-cell lung cancer - is it becoming a reality? Nat Rev Clin Oncol 7 7 2010 401 414
3. W. Pao, V.A. Miller, K.A. Politi, G.J. Riely, R. Somwar, M.F. Zakowski, M.G. Kris, and H. Varmus Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 3 2005 e73
4. S.E. Witta, R.M. Gemmill, F.R. Hirsch, C.D. Coldren, K. Hedman, L. Ravdel, B. Helfrich, R. Dziadziuszko, D.C. Chan, M. Sugita, and et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines Cancer Res 66 2 2006 944 950
5. K. Suda, K. Tomizawa, M. Fujii, H. Murakami, H. Osada, Y. Maehara, Y. Yatabe, Y. Sekido, and T. Mitsudomi Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib J Thorac Oncol 6 7 2013 1152 1161
6. T.E. Stinchcombe, and M.A. Socinski Maintenance therapy in advanced non-small cell lung cancer: current status and future implications J Thorac Oncol 6 1 2011 174 182
7. L.A. Byers, L. Diao, J. Wang, P. Saintigny, L. Girard, M. Peyton, L. Shen, Y. Fan, U. Giri, P.K. Tumula, and et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance Clin Cancer Res 19 1 2013 279 290
8. S. Thomson, E. Buck, F. Petti, G. Griffin, E. Brown, N. Ramnarine, K.K. Iwata, N. Gibson, and J.D. Haley Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition Cancer Res 65 20 2005 9455 9462
9. E.C. de Bruin, C. Cowell, P.H. Warne, M. Jiang, R.E. Saunders, M.A. Melnick, S. Gettinger, Z. Walther, A. Wurtz, G.J. Heynen, and et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer Cancer Discov 4 5 2014 606 619
10. A. Noto, C. De Vitis, G. Roscilli, L. Fattore, D. Malpicci, E. Marra, L. Luberto, A. D'Andrilli, P. Coluccia, M.R. Giovagnoli, and et al. Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer Oncotarget 4 8 2013 1253 1265
11. K. Ohashi, Y.E. Maruvka, F. Michor, and W. Pao Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease J Clin Oncol 31 8 2013 1070 1080
12. L.M. Solis, C. Behrens, W. Dong, M. Suraokar, N.C. Ozburn, C.A. Moran, A.H. Corvalan, S. Biswal, S.G. Swisher, B.N. Bekele, and et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features Clin Cancer Res 16 14 2010 3743 3753
13. M.C. Jaramillo, and D.D. Zhang The emerging role of the Nrf2-Keap1 signaling pathway in cancer Genes & development 27 20 2013 2179 2191
14. J.D. Hayes, and M. McMahon NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer Trends Biochem Sci 34 4 2009 176 188
15. G.M. DeNicola, F.A. Karreth, T.J. Humpton, A. Gopinathan, C. Wei, K. Frese, D. Mangal, K.H. Yu, C.J. Yeo, E.S. Calhoun, and et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis Nature 475 7354 2011 106 109
16. T. Yamadori, Y. Ishii, S. Homma, Y. Morishima, K. Kurishima, K. Itoh, M. Yamamoto, Y. Minami, M. Noguchi, and N. Hizawa Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers Oncogene 31 45 2012 4768 4777
17. A. Budillon, E. Di Gennaro, F. Bruzzese, M. Rocco, G. Manzo, and M. Caraglia Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents Recent patents on anti-cancer drug discovery 2 2 2007 119 134
18. E. Di Gennaro, G. Piro, M.I. Chianese, R. Franco, A. Di Cintio, T. Moccia, A. Luciano, I. de Ruggiero, F. Bruzzese, A. Avallone, and et al. Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase Br J Cancer 103 11 2010 1680 1691
19. F. Bruzzese, M. Rocco, S. Castelli, E. Di Gennaro, A. Desideri, and A. Budillon Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis Mol Cancer Ther 8 11 2009 3075 3087
20. A.A. Ruefli, M.J. Ausserlechner, D. Bernhard, V.R. Sutton, K.M. Tainton, R. Kofler, M.J. Smyth, and R.W. Johnstone The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species Proc Natl Acad Sci U S A 98 19 2001 10833 10838
21. Y.S. Dai, J. Xu, and J.D. Molkentin The DnaJ-related factor Mrj interacts with nuclear factor of activated T cells c3 and mediates transcriptional repression through class II histone deacetylase recruitment Molecular and cellular biology 25 22 2005 9936 9948
22. J.S. Ungerstedt, Y. Sowa, W.S. Xu, Y. Shao, M. Dokmanovic, G. Perez, L. Ngo, A. Holmgren, X. Jiang, and P.A. Marks Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors Proc Natl Acad Sci U S A 102 3 2005 673 678
23. F. Bruzzese, A. Leone, M. Rocco, C. Carbone, G. Piro, M. Caraglia, E. Di Gennaro, and A. Budillon HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT J Cell Physiol 226 9 2011 2378 2390
24. L. Bianchi, F. Bruzzese, A. Leone, A. Gagliardi, M. Puglia, E. Di Gennaro, M. Rocco, A. Gimigliano, B. Pucci, A. Armini, and et al. Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells Proteomics 11 18 2011 3725 3742
25. F. Tomasello, A. Messina, L. Lartigue, L. Schembri, C. Medina, S. Reina, D. Thoraval, M. Crouzet, F. Ichas, V. De Pinto, and et al. Outer membrane VDAC1 controls permeability transition of the inner mitochondrial membrane in cellulo during stress-induced apoptosis Cell Res 19 12 2009 1363 1376
26. N. Tajeddine, L. Galluzzi, O. Kepp, E. Hangen, E. Morselli, L. Senovilla, N. Araujo, G. Pinna, N. Larochette, N. Zamzami, and et al. Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death Oncogene 27 30 2008 4221 4232
27. R. Mancini, E. Giarnieri, C. De Vitis, D. Malanga, G. Roscilli, A. Noto, E. Marra, C. Laudanna, P. Zoppoli, P. De Luca, and et al. Spheres derived from lung adenocarcinoma pleural effusions: molecular characterization and tumor engraftment PLoS One 6 7 2011 e21320
28. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd New colorimetric cytotoxicity assay for anticancer-drug screening J Natl Cancer Inst 82 13 1990 1107 1112
29. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol Rev 58 3 2006 621 681
30. F. Bruzzese, B. Pucci, M.R. Milone, C. Ciardiello, R. Franco, M.I. Chianese, M. Rocco, E. Di Gennaro, A. Leone, A. Luciano, and et al. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways Cell Death Dis 4 2013 e878
31. G. Moreno-Bueno, H. Peinado, P. Molina, D. Olmeda, E. Cubillo, V. Santos, J. Palacios, F. Portillo, and A. Cano The morphological and molecular features of the epithelial-to-mesenchymal transition Nat Protoc 4 11 2009 1591 1613
32. R. Blanco, R. Iwakawa, M. Tang, T. Kohno, B. Angulo, R. Pio, L.M. Montuenga, J.D. Minna, J. Yokota, and M. Sanchez-Cespedes A gene-alteration profile of human lung cancer cell lines Human mutation 30 8 2009 1199 1206
33. J. Chen, H. Bi, J. Hou, X. Zhang, C. Zhang, L. Yue, X. Wen, D. Liu, H. Shi, J. Yuan, and et al. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells Cell Death Dis 4 2013 e814
34. A. Cavazzoni, M. Galetti, C. Fumarola, R.R. Alfieri, L. Roz, F. Andriani, P. Carbognani, M. Rusca, G. Sozzi, and P.G. Petronini Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line Cancer letters 246 1-2 2007 69 81
35. A. Singh, V. Misra, R.K. Thimmulappa, H. Lee, S. Ames, M.O. Hoque, J.G. Herman, S.B. Baylin, D. Sidransky, E. Gabrielson, and et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer PLoS Med 3 10 2006 e420
36. A.K. Maiti Genetic determinants of oxidative stress-mediated sensitization of drug-resistant cancer cells Int J Cancer 130 1 2011 1 9
37. C. Gorrini, I.S. Harris, and T.W. Mak Modulation of oxidative stress as an anticancer strategy Nat Rev Drug Discov 12 12 2013 931 947
38. V. Shoshan-Barmatz, D. Ben-Hail, L. Admoni, Y. Krelin, and S.S. Tripathi The mitochondrial voltage-dependent anion channel 1 in tumor cells Biochim Biophys Acta 2014
39. J.A. McCubrey, L.S. Steelman, F.E. Bertrand, N.M. Davis, M. Sokolosky, S.L. Abrams, G. Montalto, A.B. D'Assoro, M. Libra, F. Nicoletti, and et al. GSK-3 as potential target for therapeutic intervention in cancer Oncotarget 5 10 2014 2881 2911
40. S. Chowdhry, Y. Zhang, M. McMahon, C. Sutherland, A. Cuadrado, and J.D. Hayes Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity Oncogene 32 32 2013 3765 3781
41. S.A. Laurie, and G.D. Goss Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer J Clin Oncol 31 8 2013 1061 1069
42. S.V. Sharma, D.Y. Lee, B. Li, M.P. Quinlan, F. Takahashi, S. Maheswaran, U. McDermott, N. Azizian, L. Zou, M.A. Fischbach, and et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations Cell 141 1 2010 69 80
43. A. Edwards, J. Li, P. Atadja, K. Bhalla, and E.B. Haura Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells Mol Cancer Ther 6 9 2007 2515 2524
44. T. Nakagawa, S. Takeuchi, T. Yamada, H. Ebi, T. Sano, S. Nanjo, D. Ishikawa, M. Sato, Y. Hasegawa, Y. Sekido, and et al. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition Cancer Res 73 8 2013 2428 2434
45. K.S. McCommis, and C.P. Baines The role of VDAC in cell death: friend or foe? Biochim Biophys Acta 1818 6 2011 1444 1450
46. V. Shoshan-Barmatz, N. Keinan, S. Abu-Hamad, D. Tyomkin, and L. Aram Apoptosis is regulated by the VDAC1 N-terminal region and by VDAC oligomerization: release of cytochrome c, AIF and Smac/Diablo Biochim Biophys Acta 1797 6-7 2010 1281 1291
47. O. Sharaf el dein, C. Gallerne, C. Brenner, and C. Lemaire Increased expression of VDAC1 sensitizes carcinoma cells to apoptosis induced by DNA cross-linking agents Biochem Pharmacol 83 9 2012 1172 1182
48. A. Messina, S. Reina, F. Guarino, and V. De Pinto VDAC isoforms in mammals Biochim Biophys Acta 1818 6 2012 1466 1476
49. E. Mato, S. Barcelo-Batllori, I. Orera, L. Selva, M. Corra, C. Gonzalez, O. Bell, E. Lerma, A. Moral, J.I. Perez, and et al. The proteomic 2d-DIGE approach reveals the protein voltage-dependent anion channel 2 as a potential therapeutic target in epithelial thyroid tumours Molecular and cellular endocrinology 404C 2015 37 45
50. N. Mercado, R. Thimmulappa, C.M. Thomas, P.S. Fenwick, K.K. Chana, L.E. Donnelly, S. Biswal, K. Ito, and P.J. Barnes Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress Biochem Biophys Res Commun 406 2 2011 292 298
51. B.E. Hast, D. Goldfarb, K.M. Mulvaney, M.A. Hast, P.F. Siesser, F. Yan, D.N. Hayes, and M.B. Major Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination Cancer Res 73 7 2013 2199 2210
52. K. Sakamoto, K. Iwasaki, H. Sugiyama, and Y. Tsuji Role of the tumor suppressor PTEN in antioxidant responsive element-mediated transcription and associated histone modifications Molecular biology of the cell 20 6 2009 1606 1617
53. S. Tao, S. Wang, S.J. Moghaddam, A. Ooi, E. Chapman, P.K. Wong, and D.D. Zhang Oncogenic KRAS confers chemoresistance by upregulating NRF2 Cancer Res 74 24 2014 7430 7441
54. A.M. Traynor, S. Dubey, J.C. Eickhoff, J.M. Kolesar, K. Schell, M.S. Huie, D.L. Groteluschen, S.M. Marcotte, C.M. Hallahan, H.R. Weeks, and et al. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study J Thorac Oncol 4 4 2009 522 526
55. J. Vansteenkiste, E. Van Cutsem, H. Dumez, C. Chen, J.L. Ricker, S.S. Randolph, and P. Schoffski Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer Investigational new drugs 26 2008 483 488
56. S.S. Ramalingam, R.A. Parise, R.K. Ramanathan, T.F. Lagattuta, L.A. Musguire, R.G. Stoller, D.M. Potter, A.E. Argiris, J.A. Zwiebel, M.J. Egorin, and et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies Clin Cancer Res 13 12 2007 3605 3610
57. S.S. Ramalingam, M.L. Maitland, P. Frankel, A.E. Argiris, M. Koczywas, B. Gitlitz, S. Thomas, I. Espinoza-Delgado, E.E. Vokes, D.R. Gandara, and et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer J Clin Oncol 28 1 2010 56 62
58. T. Ma, F. Galimberti, C.P. Erkmen, V. Memoli, F. Chinyengetere, L. Sempere, J.H. Beumer, B.N. Anyang, W. Nugent, D. Johnstone, and et al. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer Mol Cancer Ther 12 8 2013 1545 1555
59. N. Reguart, R. Rosell, F. Cardenal, A.F. Cardona, D. Isla, R. Palmero, T. Moran, C. Rolfo, M.C. Pallares, A. Insa, and et al. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression Lung Cancer 84 2 2014 161 167
60. S.E. Witta, R.M. Jotte, K. Konduri, M.A. Neubauer, A.I. Spira, R.L. Ruxer, M. Varella-Garcia, P.A. Bunn Jr., and F.R. Hirsch Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy J Clin Oncol 30 18 2012 2248 2255
61. J.Y. Han, S.H. Lee, G.K. Lee, T. Yun, Y.J. Lee, K.H. Hwang, J.Y. Kim, and H.T. Kim Phase I/II study of gefitinib (Iressa) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer Cancer Chemother Pharmacol 2015
62. P.J. Roberts, T.E. Stinchcombe, C.J. Der, and M.A. Socinski Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 28 31 2010 4769 4777
63. F. Skoulidis, L.A. Byers, L. Diao, V.A. Papadimitrakopoulou, P. Tong, J. Izzo, C. Behrens, H. Kadara, E.R. Parra, J. Rodriguez-Canales, and et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities Cancer Discov 2015
64. A. Budillon, F. Bruzzese, E. Di Gennaro, and M. Caraglia Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase Current drug targets 6 3 2005 337 351
65. U.R. Rapp, C. Korn, F. Ceteci, C. Karreman, K. Luetkenhaus, V. Serafin, E. Zanucco, I. Castro, and T. Potapenko MYC is a metastasis gene for non-small-cell lung cancer PLoS One 4 6 2009 e6029
66. C. Grills, P.V. Jithesh, J. Blayney, S.D. Zhang, and D.A. Fennell Gene expression meta-analysis identifies VDAC1 as a predictor of poor outcome in early stage non-small cell lung cancer PLoS One 6 1 2011 e14635